the trelys funds  
innovation, cultivation, growth

Biolex Therapeutics Announces Expansion of Medarex Collaboration
Agreement Expanded to Include Three Medarex Monoclonal Antibodies

PITTSBORO, NORTH CAROLINA – Biolex Therapeutics today announced the expansion of its collaboration with Medarex, Inc., an antibody therapeutics company. The collaboration was initially formed in February of 2005 to create a commercial line for an undisclosed Medarex monoclonal antibody using the Biolex LEX SystemSM. As a result of the successful achievement of the scientific goals for the first monoclonal antibody, the collaboration has been expanded to include commercial line creation for two additional Medarex antibodies.

"The fact that Biolex continues to build upon and expand collaborations formed with leading monoclonal antibody companies is proof of the value and benefits of producing these important proteins with the LEX System," said Jan Turek, President and CEO of Biolex. "We have enjoyed working with Medarex and are very pleased that they are happy with the successful results we have achieved to date with their first monoclonal antibody. We plan to continue building upon and forming similar agreements with other pharmaceutical and biotech companies, while advancing our own pipeline of therapeutic proteins."

Biolex will conduct commercial line creation projects using its proprietary LEX System for each of these two additional Medarex antibodies. At Medarex’s option, it may elect to engage Biolex to scale-up and manufacture these proteins following the commercial line creation phase.

About Biolex Therapeutics
Biolex Therapeutics applies its unique drug development capabilities and expertise to commercialize complex proteins and monoclonal antibodies. Biolex’ patented LEX System uses Lemna as a transgenic host in its GMP biopharmaceutical manufacturing facility to produce therapeutic proteins to support its own development programs as well as the programs of its strategic partners. The company is advancing a proprietary pipeline of product candidates, including its lead program Locteron™ for the treatment of hepatitis C under joint development with OctoPlus. Biolex has a multi-protein strategic alliance with Centocor and collaborations with other pharmaceutical/biotech companies including Medarex. Biolex is a venture-capital backed company located in the Research Triangle region of North Carolina, United States. For additional information, please visit Biolex’ web site at

© the trelys funds